NIH Allergy Institute Taps Emergent BioSolutions for Anthrax Vaccine Dry Formulation; Adam Havey Comments
Emergent BioSolutions has landed a five-year, $29 million contract with the National Institute of Allergy and Infectious Diseases to make a dry formulation of the NuThrax anthrax vaccine candidate in an effort to facilitate shipping and storage at normal temperatures. The company said Monday the contract covers manufacturing, non-clinical processes and application to the U.S. Food and Drug Administration for Investigational New Drug status. “We […] More